NCT03373604

Imaging Tau in Alzheimer's Disease and Normal Aging

Imaging Tau in Alzheimer's Disease and Normal Aging With 18F-MK-6240

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 71 (actual)
• Sponsor: Patrick Lao · Academic / Other
• Sex: All
• Age: 50 Years – 100 Years
• Healthy volunteers: Accepted

Summary

This study is being done to learn about tau tangles in Alzheimer's disease. A type of positron emission tomography (PET) scan is used to measure the abnormal accumulation of protein called tau in the brain. These are thought to be involved in Alzheimer's disease. The investigators will also perform brain MRI and to tests to measure the participant's memory and thinking.

Detailed description

This study is being done to determine the relationship between tau tangles and cognitive impairment in elderly subjects with and without Alzheimer's disease (AD). Subjects will undergo screen that includes neuropsychological testing and brain MRI. This study uses a special type of scan called a PET scan to take pictures of the brain. During the PET scan, a special radioactive dye called 18F-MK-6240 is injected into the body. 18F-MK-6240 sticks to abnormal tangles made of the protein tau. Subjects will have the option to have lumbar puncture performed to measure CSF concentrations of biomarkers.

Conditions

• Alzheimer Disease

Interventions

Type	Name	Description
DRUG	18F-MK-6240	18F-MK-6240 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.
PROCEDURE	Lumbar Puncture (optional)	Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.

Timeline

• Start date: 2017-12-11
• Primary completion: 2022-05-11
• Completion: 2022-05-11
• First posted: 2017-12-14
• Last updated: 2025-05-08
• Results posted: 2025-05-08

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study